Table 5.
Independent factors for pre-existing rtM204I variants in treatment-naïve chronic hepatitis B patients
| Pre-existing rtM204I (n = 17) | Wild type rtM204 (n = 386) |
Univariate |
Multivariate |
|||||
| OR | 95%CI | P value | OR | 95%CI | P value | |||
| Gender (male) | 14 (82.4%) | 230 (59.6%) | 3.165 | (0.895-11.197) | 0.074 | |||
| Age, yr | 48.8 ± 9.3 | 43.7 ± 12.6 | 1.033 | (0.993-1.074) | 0.105 | |||
| HBeAg status (positive) | 10 (58.8%) | 228 (59.1%) | 0.990 | (0.369-2.656) | 0.984 | |||
| HBV-DNA, log10 IU/mL | 6.33 ± 0.66 | 6.06 ± 1.77 | 1.098 | (0.827-1.458) | 0.519 | |||
| qHBsAg, log10 IU/mL | 3.43 ± 0.30 | 3.59 ± 0.70 | 0.555 | (0.336-0.916) | 0.021 | |||
| AST, IU/L | 104.7 ± 40.9 | 78.7 ± 65.2 | 1.005 | (0.999-1.011) | 0.109 | |||
| ALT, IU/L | 77.8 ± 29.4 | 85.4 ± 84.1 | 0.999 | (0.992-1.005) | 0.709 | |||
| Total bilirubin, mg/dL | 0.93 ± 0.33 | 0.88 ± 0.60 | 1.140 | (0.522-2.487) | 0.742 | |||
| Albumin, g/dL | 4.02 ± 0.43 | 4.14 ± 0.52 | 0.655 | (0.275-1.559) | 0.339 | |||
| Prothrombin time, INR | 1.07 ± 0.10 | 1.02 ± 0.16 | 4.625 | (0.339-63.020) | 0.250 | |||
| Platelet count, × 103/mm3 | 155.7 ± 55.6 | 181.4 ± 64.4 | 0.993 | (0.985-1.001) | 0.108 | |||
| Significant fibrosis1 | 12 (70.6%) | 145 (37.6%) | 3.989 | (1.377-11.553) | 0.011 | 3.397 | (1.119-10.319) | 0.031 |
| Liver cirrhosis | 7 (41.2%) | 80 (20.7%) | 2.677 | (0.988-7.255) | 0.053 | |||
| HCC | 5 (29.4%) | 46 (11.9%) | 3.080 | (1.038-9.139) | 0.043 | 1.961 | (0.626-6.143) | 0.248 |
1
Significant fibrosis was defined as aspartate aminotransferase to platelet ratio index > 1.5 or fibrosis-4 index > 3.25. ALT: Alanine aminotransferase; APRI: Aspartate aminotransferase to platelet ratio index; AST: Aspartate aminotransferase; FIB-4: Fibrosis-4 Index; HCC: Hepatocellular carcinoma; INR: International normalized ratio; qHBsAg: Quantitative hepatitis B surface antigen levels; HBV: Hepatitis B virus.